Tech Company Financing Transactions

Accent Therapeutics Funding Round

Accent Therapeutics, operating out of Lexington, secured $75 million in investment from Mirae Asset Capital, AbbVie Biotech Ventures and Atlas Venture.

Transaction Overview

Company Name
Accent Therapeutics
Announced On
1/23/2024
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series C
Investors

Mirae Asset Capital (Lead Investor)

AbbVie Biotech Ventures

Atlas Venture (Jason Rhodes)

Bristol Myers Squibb

Droia Ventures

EcoR1 Capital Management (Oleg Nodelman)

GV

Johnson & Johnson Innovation

Mirae Asset Venture Investment

NS Investment

The Column Group (Larry Lasky)

The Mark Foundation for Cancer Research

Proceeds Purpose
The company intends to use the funds to advance its both lead programs --Accent's first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor -- through early clinical development including safety, pharmacokinetics and early efficacy studies.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Hayden Ave.
Lexington, MA 02421
USA
Phone
(339) 970-7400
Website
www.accenttx.com
Email Address
[email protected]
Overview
Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics.
Profile
Accent Therapeutics LinkedIn Company Profile
Social Media
Accent Therapeutics Company Twitter Account
Company News
Accent Therapeutics News
Facebook
Accent Therapeutics on Facebook
YouTube
Accent Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Shakti Narayan
  Shakti Narayan LinkedIn Profile  Shakti Narayan Twitter Account  Shakti Narayan News  Shakti Narayan on Facebook
Chief Financial Officer
Nicole Heifner
  Nicole Heifner LinkedIn Profile  Nicole Heifner Twitter Account  Nicole Heifner News  Nicole Heifner on Facebook
President
Robert Copeland
  Robert Copeland LinkedIn Profile  Robert Copeland Twitter Account  Robert Copeland News  Robert Copeland on Facebook
Vice President
Ann Boriack-Sjodin
  Ann Boriack-Sjodin LinkedIn Profile  Ann Boriack-Sjodin Twitter Account  Ann Boriack-Sjodin News  Ann Boriack-Sjodin on Facebook
Vice President
Kenneth Duncan
  Kenneth Duncan LinkedIn Profile  Kenneth Duncan Twitter Account  Kenneth Duncan News  Kenneth Duncan on Facebook
Vice President
Scott Ribich
  Scott Ribich LinkedIn Profile  Scott Ribich Twitter Account  Scott Ribich News  Scott Ribich on Facebook
VP - Bus. Development
David Brower
  David Brower LinkedIn Profile  David Brower Twitter Account  David Brower News  David Brower on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/23/2024: Bluewhite venture capital transaction
Next: 1/23/2024: Albedo venture capital transaction

 

Share this article

 

About Database of VC Transactions

We record funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.